Agile Therapeutics Announces Proposed Offering of Common Stock
03 8월 2017 - 5:05AM
Agile Therapeutics, Inc. (Nasdaq:AGRX), a forward-thinking women’s
healthcare company, today announced that it intends to offer and
sell shares of its common stock, subject to market and other
conditions, in an underwritten public offering. All shares being
offered are to be sold by Agile Therapeutics. Agile
Therapeutics intends to grant the underwriters a 30-day option to
purchase an additional fifteen percent of the shares of common
stock offered in the public offering.
The joint book-running managers for the offering
are William Blair, RBC Capital Markets, and Cantor Fitzgerald
& Co.
The shares of common stock described above are
being offered by Agile Therapeutics pursuant to its shelf
registration statement on Form S-3 previously filed and declared
effective by the Securities and Exchange Commission. The
offering is being made only by means of a preliminary prospectus
supplement and the accompanying prospectus, copies of which may be
obtained, when available, from William Blair & Company, L.L.C.,
Attention: Prospectus Department, 150 North Riverside
Plaza, Chicago, IL 60606; Telephone: (800) 621-0687 or by
email at prospectus@williamblair.com, RBC Capital Markets,
LLC, 200 Vesey Street, 8th Floor, New York,
NY 10281-8098; Attention: Equity Syndicate; Tel: (877)
822-4089; email: equityprospectus@rbccm.com; and Cantor Fitzgerald
& Co., Attention: Capital Markets, 499 Park Avenue, 6th Floor
New York, New York 10022; email: prospectus@cantor.com.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy these securities, nor
shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Agile Therapeutics,
Inc.
Agile Therapeutics is a forward-thinking women's
healthcare company dedicated to fulfilling the unmet health needs
of today’s women. Our product candidates are designed to provide
women with contraceptive options that offer freedom from taking a
daily pill, without committing to a longer-acting method. Our lead
product candidate, Twirla®, (ethinyl estradiol and levonorgestrel
transdermal system), also known as AG200-15, is a once-weekly
prescription contraceptive patch that recently completed Phase 3
trials. Twirla is based on our proprietary transdermal patch
technology, called Skinfusion®, which is designed to provide
advantages over currently available patches and is intended to
optimize patch adhesion and patient wearability.
Forward-Looking Statement
Certain information contained in this press
release includes "forward-looking statements" within the meaning of
The Private Securities Litigation Reform Act of 1995, including
statements related to our public offering and potential market
opportunity for our product candidates. We may, in some cases use
terms such as "predicts," "believes," "potential," "continue,"
"anticipates," "estimates," "expects," "plans," "intends," "may,"
"could," “might," "will," "should" or other words that convey
uncertainty of the future events or outcomes to identify these
forward-looking statements. Our forward-looking statements are
based on current expectations that involve risks, potential changes
in circumstances, assumptions and uncertainties. Any or all of the
forward-looking statements may turn out to be wrong, or be affected
by inaccurate assumptions we might make or by known or unknown
risks and uncertainties as a result of various important factors,
including the uncertainties related to market conditions and the
completion of the public offering on the anticipated terms or at
all and such other factors. For a further description of the
risks and uncertainties that could cause actual results to differ
from those expressed in these forward-looking statements, as well
as risks relating to our business in general, please refer to our
prospectus supplement to be filed with the Securities and Exchange
Commission (SEC) on August 2, 2017 under the heading “Risk Factors”
and those documents incorporated by reference therein, which
includes our Quarterly Report on Form 10-Q filed with the SEC on
July 28, 2017. You are cautioned not to place undue reliance on
these forward-looking statements, which are made only as of the
date of this press release. We undertake no obligation to publicly
update such forward-looking statements to reflect subsequent events
or circumstances.
Contact: Mary Coleman -- 609-356-1921
Agile Therapeutics (NASDAQ:AGRX)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Agile Therapeutics (NASDAQ:AGRX)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024